Država: Avstralija
Jezik: angleščina
Source: Department of Health (Therapeutic Goods Administration)
methylprednisolone sodium succinate, Quantity: 53 mg (Equivalent: methylprednisolone, Qty 40 mg)
MedTAS Pty Ltd
methylprednisolone sodium succinate
Injection, powder for
Excipient Ingredients: monobasic sodium phosphate dihydrate; lactose monohydrate; dibasic sodium phosphate; sodium carbonate
Intramuscular, Intravenous
1's, 5's
(S4) Prescription Only Medicine
When oral therapy is not feasible & strength, dosage form & route of administration of drug reasonably lend preparation to treatment of following conditions. Intravenous or intramuscular use only.,Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is drug of choice; mineralocorticoid supplementation may be necessary particularly when synthetic analogues are used). Preoperatively & in event of serious trauma or illness in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or suspected, congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcaemia associated with cancer. Congenital adrenal hy
Visual Identification: White to off white lyophilised plug or powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2009-04-08
METHYLPRED _methylprednisolone (as sodium succinate) powder for injection_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about METHYLPRED. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given METHYLPRED against the benefits they expect it will have for you. FOLLOW THE INSTRUCTIONS GIVEN TO YOU BY YOUR DOCTOR AND ADVICE CONTAINED IN THIS LEAFLET. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT METHYLPRED IS USED FOR METHYLPRED contains methylprednisolone (as methylprednisolone sodium succinate) as the active ingredient. It belongs to a group of medicines called corticosteroids. It is used for the treatment of one or more of the following conditions: • skin diseases • allergic reactions • inflammation of the eyes • respiratory diseases and certain respiratory infections • diseases of the gut (gastrointestinal tract) • multiple sclerosis • rheumatic disorders • diseases of the blood • treatment of certain glandular conditions _HOW YOUR MEDICINE WORKS_ METHYLPRED reduces inflammation (pain, swelling, redness and heat) which is one of the body's reactions to injury and by reducing the body's reaction to infection. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another purpose. It is available only with a doctor's prescription. There is no evidence that it is addictive. BEFORE YOU ARE GIVEN IT _WHEN METHYLPRED MUST NOT_ _BE USED_ You must not be given METHYLPRED if you have an allergy to: • any medicine containing methylprednisolone sodium succinate • any of the ingredients listed at the end of this leaflet. The METHYLPRED 40 mg product contains lactose from cow's milk. TELL YOUR DOCTOR IF YOU A Preberite celoten dokument
AUSTRALIAN PRODUCT INFORMATION METHYLPRED _Methylprednisolone (as sodium succinate) powder for injection _ 1 NAME OF THE MEDICINE Methylprednisolone sodium succinate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION METHYLPRED powder for injection contains 40 mg, 125 mg, 500 mg or 1.0 g methylprednisolone (as methylprednisolone sodium succinate) as the active ingredient. List of excipients with known effect: lactose (40 mg strength only). For the full list of excipients, see section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM METHYLPRED is a white to off white lyophilised plug or powder _ _ 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS When oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the following conditions. For intravenous or intramuscular use only. ENDOCRINE DISORDERS • Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). • Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). • Preoperatively and in the event of serious trauma or illness in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. • Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected • congenital adrenal hyperplasia, • nonsuppurative thyroiditis, • hypercalcaemia associated with cancer. RHEUMATIC DISORDERS As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: • ankylosing spondylitis, • psoriatic arthritis, • acute and subacute bursitis, • synovitis of osteoarthritis, • acute nonspecific tenosynovitis, • epicondylitis, • acute gouty ar Preberite celoten dokument